Amgen completes $27.8B acquisition of Horizon Therapeutics
Mario Tama
Amgen (NASDAQ:AMGN) completed its $27.8 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP) after receiving final regulatory approval for the deal. 
"We have strong momentum in our core business, and the addition of Horizon will further position Amgen as a leader across a broader range of diseases," "Amgen (AMGN) CEO and Chairman Robert A. Bradway said in a statement on Friday.
Amgen (AMGN) closed its purchase of Horizon (HZNP) for $116.50 a share after it won approval from the High Court of Ireland for the deal on Thursday.
The Federal Trade Commission last month settled with Amgen (AMGN) and Horizon (HZNP) to allow the combination to move forward.

More on Amgen

Confirmatory Trial Trouble In KRAS
Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
Amgen Inc. (AMGN) Citi Global Healthcare Conference (Transcript)
FDA panel finds results from key Amgen Lumakras study unreliable
Amgen wins Irish approval for planned Horizon Therapeutics purchase